制药、生物科技与生命科学行业上市公司E维度绩效对比分析：2024年度 VS 2023年度（上）

Core Insights - The implementation of ESG principles has become a global trend, particularly accelerated in China under the dual carbon goals and high-quality development strategies, making ESG a mandatory aspect for companies in the pharmaceutical, biotechnology, and life sciences sectors [1] Group 1: ESG Reporting and Performance - As of May 5, 2025, 161 companies in the A-share pharmaceutical, biotechnology, and life sciences sector have actively disclosed their 2024 ESG reports, compared to 134 companies for 2023 [2] - The UCCR ESG team conducted a comprehensive analysis of the E (Environmental) performance of these companies for 2023 and 2024, using their ESG rating model and standards [2] Group 2: Environmental Management Goals - In 2024, 67.08% of companies established clear environmental management goals, a significant increase from 41.04% in 2023, marking a rise of 26.04% [3] - In 2024, 32.30% of companies had somewhat clear environmental management goals needing further refinement, down from 58.96% in 2023, a decrease of 26.66% [3] Group 3: Energy Conservation and Renewable Resources - In 2024, 93.79% of companies formulated policies on energy conservation and renewable resources, compared to 100% in 2023 [6] - The percentage of companies with comprehensive policies to effectively promote ESG construction decreased slightly from 48.51% in 2023 to 47.20% in 2024 [6] Group 4: Environmental Information Disclosure - In 2024, 59.01% of companies established dedicated departments for environmental information disclosure, an increase from 47.76% in 2023 [8] - The proportion of companies with complete and high-quality environmental information disclosure rose from 16.42% in 2023 to 35.40% in 2024 [10] Group 5: Resource Recycling and Waste Management - In 2024, 6.83% of companies had high levels of resource recycling, down from 20.15% in 2023, indicating a decline of 13.32% [12] - The percentage of companies with environmentally friendly waste disposal methods decreased from 23.13% in 2023 to 10.56% in 2024, a drop of 12.57% [14]